Novartis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Comparison of Two Treatment Strategies in Hypertensive Patients
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 4445
- Registration Number
- NCT00171444
Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 130
- Registration Number
- NCT00171535
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia
Phase 3
Completed
- Conditions
- Heterozygous Familial HypercholesterolemiaMixed Dyslipidemia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 84
- Registration Number
- NCT00171236
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Antialbuminuric Effects of Valsartan and Lisinopril
Phase 4
Terminated
- Conditions
- HypertensionEarly Diabetic Nephropathy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 54
- Registration Number
- NCT00171600
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone
Phase 3
Completed
- Conditions
- Dyslipidemia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 83
- Registration Number
- NCT00171288
- Locations
- 🇪🇸
Novartis, Madrid, Spain
Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 144
- Registration Number
- NCT00171561
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00171028
- Locations
- 🇺🇸
Novartis Pharmaceuticals, E. Hanover, New Jersey, United States
A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 109
- Registration Number
- NCT00171353
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 125
- Registration Number
- NCT00171054
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
Phase 1
Completed
- Conditions
- TumorsNeoplasm Metastasis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 22
- Registration Number
- NCT00171587
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States